Revolution Medicines awarded voucher for Daraxonrasib by FDA

Revolution Medicine “announced that the U.S. Food and Drug Administration has granted a non-transferrable voucher for daraxonrasib, the company’s RAS multi-selective inhibitor, under the Commissioner’s National Priority Voucher pilot program. Daraxonrasib is being studied in two global Phase 3 clinical trials, RASolute 302 in patients with previously treated metastatic pancreatic ductal adenocarcinoma and RASolve 301 in patients with previously treated metastatic non-small cell lung cancer.”